New Jersey

The policy story shifted materially between 2024 and early 2026. Earlier versions of S2283 contemplated a broader behavioural-health access and services framework, but Assembly amendments adopted on 12 Jan 2026 revised the bill into the narrower pilot-program model that was ultimately signed. That narrowing matters for analysts because it moves New Jersey from “possible public access state” to “state-funded, hospital-based pilot state.”###

Budget documents reinforce that interpretation. The New Jersey budget analysis describes the pilot as a two-year programme with one hospital selected from each region of the state and notes that the Executive’s FY2027 recommendation does not continue the one-time FY2026 $6 million supplemental appropriation. That does not repeal the law, but it does signal that ongoing scale-up should not be assumed without further legislative or budget action.###

New Jersey now has both policy-backed and privately organised research activity. ClinicalTrials.gov listings show New Jersey locations for Usona’s phase 3 psilocybin trial in major depressive disorder in Princeton, and Compass’s earlier psilocybin MDD study listed a Berlin, New Jersey location at Hassman Research Institute. Cybin’s CYB003 programme also lists Princeton, New Jersey.###

The enacted state pilot could further concentrate new research activity inside the three selected hospitals once implementation proceeds. Outside that pilot, New Jersey’s visible ecosystem includes site-level clinical research capacity at organisations such as Princeton Medical Institute, plus professional-education activity at Rutgers and advocacy/professional networking through the New Jersey Psychedelic Therapy Association.###

Implementation sits with the Department of Health and the Psychedelic Therapy and Research Board. The enacted law and budget analysis show a clear structure: a dedicated research fund, three hospital awards, a two-year pilot, and later reporting on findings and recommendations for possible statewide rollout.###

What remains uncertain is operational execution. The reviewed sources did not verify that the DOH had already selected the three hospitals by 18 May 2026. That is a material uncertainty because actual patient access depends on hospital designation, protocol development, federal controlled-substance compliance, staffing, and hospital IRB/research infrastructure rather than the existence of the statute alone.###

New Jersey’s ecosystem is becoming more layered, but it is still not a broad public-access market. Princeton Medical Institute and Hassman Research Institute appear in national psilocybin trials, Rutgers has hosted ketamine-assisted psychotherapy education and research-facing events, and Rutgers Health researchers have also published or publicly discussed ketamine-related work.###

The state also has visible advocacy and practitioner-network infrastructure. NJPTA presents itself as a New Jersey-focused organisation supporting therapist education and advocacy. That matters for workforce development, but it should not be confused with state licensure or authorised psilocybin service delivery.###

Over the next 12 to 24 months, the real question is whether implementation produces a credible hospital pilot with named sites, functioning protocols, and publicly intelligible outcome reporting. If hospital selection occurs and federal research compliance is handled cleanly, New Jersey could become a highly watched model for “research-first” state policy.###

But patient access should not be overstated. New Jersey has not created FDA-approved psilocybin treatment, and the FY2027 budget signal suggests that continuation or expansion will require fresh political support. For payers, investors, and conference partners, the watch items are hospital selection, protocol publication, board activity, and whether lawmakers return to a broader medical-access bill after the pilot generates data.###